KAKAKU.COM
26.6.2024 15:01:31 CEST | Business Wire | Press release
Tabelog*2, one of Japan’s largest restaurant search and reservation sites, has launched an online reservation service for visitors to Japan, which supports English, Chinese (Simplified and Traditional) and Korean. With reservations available at over 35,000 restaurants, it is the largest service of its kind in Japan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240626189960/en/
Reservation Flow (Graphic: Business Wire)
*1As of June 26, 2024, based on internal research. Largest restaurant reservation service (instant reservations) for visitors to Japan
*2Tabelog is operated by Kakaku.com, Inc. one of Japan’s leading Internet companies.
Tabelog’s online reservation service for overseas visitors
To offer a more convenient way to find and reserve restaurants for the growing number of visitors to Japan, we have launched an online restaurant reservation service where reservations can be made in English, Chinese (Traditional and Simplified), and Korean.
*According to the Japan National Tourism Organization, the number of visitors to Japan is expected to exceed 3 million in May 2024 (up 60% from the previous year).
Features of Tabelog’s service are as follows:
- Search for restaurants in Japan by specifying a location, cuisine, budget, and the date and time you want to make a reservation.
- Select a restaurant based on detailed information about the restaurant, including menu, photos, and reviews posted by Japanese users.
-
Check reservation availability using the calendar function and make online reservations directly on Tabelog.
*Online reservations are currently only available for set menus and require credit card registration. In addition, there is a system usage fee of 440 yen (incl. tax) per person per reservation.
“Japan is currently the destination of choice for travelers from around the world, and many of them want to experience Japan’s food culture. However, there is still a shortage of restaurants equipped to communicate with and take reservations from overseas visitors leading to a situation where only a handful of well-known restaurants are attracting visitors to Japan,” said Taku Kounoike, Head of Tabelog. “As a Japanese gourmet media, we want to support travelers in experiencing the deeper charm of Japan, by showcasing a wide range of excellent restaurants across the country, and by providing a service that enables users to make online reservations. We sincerely hope that your travel experience in Japan will become more fulfilling than ever before.”
Links to the different language versions of Tabelog:
- English: https://tabelog.com/en/
- Simplified Chinese: https://tabelog.com/cn/
- Traditional Chinese: https://tabelog.com/tw/
- Korean: https://tabelog.com/kr/
*Ongoing modifications and improvements to the site may result in changes to the user interface and performance.
About Tabelog
Tabelog provides information on almost all restaurants in Japan, and users can choose restaurants catering to their specific preferences, based on information provided by the restaurants themselves, as well as reviews and photos posted by users. The service receives high marks from users for offering comprehensive information about restaurants and a highly convenient user interface. As of March 2024, it has become one of Japan’s largest restaurant search and reservation services, with approximately 93.5 million monthly users.
About Kakaku.com, Inc. (https://corporate.kakaku.com/?lang=en)
Established in 1997, Kakaku.com, Inc. (TOKYO:2371) is a Japanese internet company operating various web services, including the purchasing support site "Kakaku.com", the restaurant search and reservation service "Tabelog", and the comprehensive job search service "Kyujin Box". In April 2024, the company launched "Jobcube", a comprehensive search site for jobseekers, in the United States.
Service Overview: https://corporate.kakaku.com/company/service/?lang=en
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240626189960/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom